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Optineurin (OPTN) was identified 20 years ago in a yeast-two-hybrid screen with a viral 
protein known to inhibit the cytolytic effects of tumor necrosis factor. Since then, OPTN 
has been identified as a ubiquitin-binding protein involved in many signaling pathways 
and cellular processes, and mutations in the OPTN gene have been associated with 
glaucoma, Paget’s disease of bone and neurodegenerative pathologies. Its role in auto-
phagy, however, has attracted most attention in recent years and may explain (some of) 
the mechanisms behind the disease-associated mutations of OPTN. In this brief review, 
we focus on the role of OPTN in inflammation and immunity and describe how this may 
translate to its involvement in human disease.
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inTRODUCTiOn
Optineurin (OPTN) was first identified as a binding partner of an adenoviral E3 14.7 kDa protein 
and named “FIP-2” (for E3-14.7K-interacting protein) but after renamed to “optineurin” (for optic 
neuropathy inducing) since mutations in the OPTN gene had been identified in patients with pri-
mary open-angle glaucoma (1, 2). Later on, OPTN mutations were also identified in other human 
pathologies including Paget disease of bone, amyotrophic lateral sclerosis (ALS) and frontotemporal 
dementia (FTD) (3–5), explaining the growing interest of the scientific community for this gene.
Optineurin has been characterized as a multifunctional protein regulating multiple cellular pro-
cesses such as vesicular trafficking, cell division, inflammatory and antiviral signaling, anti-bacterial 
responses, and autophagy. OPTN can bind multiple partners; hence, disease-causing mutations may 
alter these interactions disturbing normal signaling (Figure 1). However, many questions remain, 
and more evidence is needed to clarify its multiple functions and contribution to disease.
OPTn AnD nUCLeAR FACTOR-κB (nF-κB) SiGnALinG
Inflammatory signaling pathways, and especially NF-κB signaling, are heavily controlled by ubiqui-
tination, a posttranslational modification of proteins. Polyubiquitin chain formation through lysine 
48 (K48) of ubiquitin directs proteasomal degradation of the modified protein. By contrast, K63 or 
linear (M1) ubiquitination normally do not lead to degradation of the protein but mediate the bind-
ing of other proteins that contain specific ubiquitin-binding domains (UBDs), driving downstream 
signaling (6). OPTN’s sequence shows striking homology to NF-κB essential modulator (NEMO), 
the core regulatory element of the inhibitor of NF-κB kinase (IKK) complex essential for NF-κB 
activation (7). Both OPTN and NEMO have a similar UBD which facilitates binding to M1 and 
K63-linked ubiquitin chains, but not to the K48-linked ones (8). Despite their sequence homol-
ogy, OPTN cannot substitute NEMO in the IKK complex (9). Initially, in vitro studies identified 
FiGURe 1 | Schematic representation of OPTN protein structure, interaction partners, and most common POAG- and ALS-associated mutations (indicated in red). 
Abbreviations: ALS, amyotrophic lateral sclerosis; CC, coiled coil; CYLD, cylindromatosis; E3-14.7K, early region 3 14.7 kDa protein; LIR, LC3-interacting region; 
POAG, primary open-angle glaucoma; RIPK1, receptor-interacting protein kinase 1; TBK1, TANK-binding kinase 1; UBD; ubiquitin-binding domain; ZF, zinc finger; 
OPTN, optineurin.
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OPTN as a negative regulator of NF-κB signaling in response 
to tumor necrosis factor (TNF) by competing with NEMO for 
binding to ubiquitinated receptor-interacting protein kinase 1 
(RIPK1), dampening downstream inflammatory signaling (7, 10) 
(Figure 2A). Recent structural studies showed that linear ubiqui-
tin binding by the OPTN UBD is critical for NF-κB suppression 
(11). OPTN was also shown to interact with cylindromatosis 
(CYLD), a deubiquitinating enzyme that cleaves linear and K63-
linked ubiquitin chains from proteins such as NEMO and RIPK1, 
to block downstream NF-κB signaling (12). OPTN has also been 
identified as a binding partner of interleukin-1 (IL-1) receptor-
associated kinase 1 (IRAK-1), where it suppresses NF-κB activa-
tion in response to IL-1β and toll-like receptor stimulation by 
preventing the poly-ubiquitination of TRAF6 (13) (Figure 2B). 
A mutant version of OPTN that fails to recruit CYLD to inhibit 
NF-κB activation in response to TNF is also unable to inhibit 
IRAK-1-induced NF-κB signaling (12, 13). Finally, OPTN was 
recently shown to suppress T cell receptor-induced NF-κB activa-
tion and TNF production, in a manner dependent on ubiquitin-
binding (14).
In contrast to these in  vitro studies, in  vivo studies do not 
confirm a role for OPTN in NF-κB signaling. OPTN[D477N] 
knock-in mice expressing a point mutation abolishing its 
polyubiquitin-binding activity, as well as mice lacking either the 
entire C-terminal UBD or the N-terminal TBK1-binding domain, 
show normal NF-κB responses (8, 15, 16). Also, OPTN deficiency 
does not affect TNF nor TLR-induced NF-κB activation, arguing 
against a role for OPTN in the regulation of NF-κB signaling 
in vivo (17).
OPTn AnD inTeRFeROn (iFn) SiGnALinG
The production of type I IFNs is an essential initial step in the host 
defense against infections (18). Bacterial LPS and viral double-
stranded RNA (dsRNA) induce immune responses through the 
activation of TBK1, the phosphorylation of IFN regulatory factor 
3 (IRF3), and the production of type I IFNs. OPTN can bind to 
TBK1, but not to the related kinase IKKε (8, 19). Bone marrow 
derived macrophages (BMDMs) from OPTN-deficient mice 
(17) or from OPTN mutant mice lacking the UBD or the TBK1-
interacting region (15, 16) show diminished phosphorylation of 
TBK1 and IRF3 and as a result secrete lower levels of IFN-β in 
response to LPS or the dsRNA mimetic poly(I;C) (Figure 2C). 
Also BMDMs from ubiquitin-binding-defective OPTN[D477N] 
mutant mice show reduced TBK1 activity, IRF3 phosphorylation 
and production of IFN-β in response to LPS or poly(I;C) (8). 
Recent work from Bakshi and colleagues indeed shows that the 
interaction between ubiquitin chains and OPTN is required 
for robust phosphorylation and activation of the OPTN-TBK1 
complex, triggering IRF3 activation and IFN-β production (20).
OPTn AnD AUTOPHAGY
With the identification of OPTN as an autophagy receptor, a 
new era of research on OPTN started. Autophagy is a lysosomal 
degradation pathway important for the removal of protein aggre-
gates, intracellular bacteria and damaged cellular organelles (21). 
In 2011, the group of Ivan Dikic demonstrated that OPTN can 
bind to the autophagy protein LC3 via an LC3-interacting (LIR) 
motif, and with ubiquitin via its UBD. Upon infection of cells 
with Salmonella, OPTN associates with ubiquitin-coated bacteria 
and recruits TBK1 that phosphorylates OPTN, enhancing its LC3 
binding affinity, through which it promotes the autophagic clear-
ance of bacteria (22, 23). Also in vivo, OPTN was shown to con-
trol Salmonella infection (17, 22, 23). Upon infection, invading 
Salmonella bacteria become decorated with ubiquitin chains that 
serve as a platform to trigger various signaling cascades (24). This 
coat of ubiquitin around the bacteria is not uniform but contains 
distinct patterns of both linear and K63-linked chains eliciting 
different downstream signaling pathways (24, 25). Linear ubiq-
uitination at the bacterial surface induces the recruitment of 
OPTN and NEMO, activating selective autophagy and inducing 
IKK activation and NF-κB-dependent inflammatory signaling, 
respectively, restricting bacterial proliferation (24, 25). The origin 
of M1-linked polyubiquitin in the ubiquitin coat on the bacterial 
surface is most probably caused by the localized recruitment 
of the M1-specific E3 ubiquitin ligase complex LUBAC (25) 
(Figure 2D). Besides OPTN, also other autophagy receptors, such 
FiGURe 2 | Optineurin (OPTN) in cellular signaling. (A) Upon activation of tumor necrosis factor (TNF) receptor 1, OPTN is recruited to the receptor complex where 
it competes with nuclear factor-κB (NF-κB) essential modulator (NEMO) for ubiquitinated RIPK1. OPTN can also recruit the deubiquitinating enzyme cylindromatosis 
(CYLD), which cleaves off ubiquitin chains from proteins such as NEMO and RIPK1, blocking downstream NF-κB signaling. (B) Upon activation of IL-1 and TLR 
receptors with their respective ligands, the adaptor protein MyD88 is recruited to the receptor complex where it engages the kinase interleukin-1 (IL-1) receptor-
associated kinase 1 (IRAK-1) and the E3 ligase TRAF6, inducing TRAF6 auto-ubiquitination and downstream NF-κB signaling. OPTN can bind IRAK-1 through its 
ubiquitin-binding domain preventing TRAF6 ubiquitination and suppressing downstream NF-κB signaling. This process may involve the recruitment of CYLD.  
(C) Bacterial LPS and viral double-stranded RNA (dsRNA) induce the activation of TANK-binding kinase 1 (TBK1), which binds and phosphorylates OPTN, leading 
to the phosphorylation, dimerization, and nuclear translocation of IFN regulatory factor 3 (IRF3), mediating the transcription of interferon type I response genes.  
(D) OPTN acts as an autophagy receptor that associates with ubiquitin-coated cytosolic bacteria and recruits TBK1 to phosphorylate OPTN, enhancing its LC3 
binding affinity, directing autophagosomal degradation. The LUBAC complex (consisting of Sharpin, HOIL-1, and HOIP) mediates the linear ubiquitination at the 
bacterial surface inducing the recruitment of NEMO and OPTN to activate NF-κB signaling and autophagy. (e) Damaged mitochondria are removed through 
mitophagy, a process involving the kinase PINK1 and the E3 ubiquitin ligase Parkin, which conjugates ubiquitin to mitochondrial outer membrane proteins, recruiting 
OPTN. This process involves TBK1-dependent OPTN phosphorylation promoting the autophagosomal degradation of mitochondria. (F) OPTN can bind caspase 8, 
limiting complex II formation and apoptosis. Alternatively, OPTN can regulate the turnover of ubiquitinated RIPK1 protecting from necroptosis.
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as p62 and NDP52, are recruited to autophagosomal membranes 
through their LIR motifs. However, the recruitment of p62 and 
NDP52 occurs independently of LUBAC (25), demonstrating 
that, although there are multiple autophagy receptors, their 
functions are not completely redundant. Instead, they depend on 
their specific interacting partners and the downstream signaling 
cascades they activate.
Besides its role in the autophagy-mediated elimination of 
intracellular pathogens (xenophagy), OPTN also controls the 
selective autophagy of damaged mitochondria which also become 
conjugated with ubiquitins. This process of mitophagy depends 
on the kinase PINK1 and the E3 ligase Parkin, which, upon 
activation, ubiquitinates mitochondrial outer membrane proteins 
to recruit autophagy receptors. Mitophagy also involves TBK1 
activation, leading to its translocation to mitochondria where it 
phosphorylates OPTN thereby expanding the binding capacity 
of OPTN to diverse ubiquitin chains, directing ubiquitin-loaded 
mitochondria into autophagosomes (Figure 2E) (23, 26, 27).
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OPTn AnD DiSeASe-ASSOCiATeD 
MUTATiOnS
Considerable interest in OPTN came from the identification 
of mutations in the OPTN gene in patients with degenerative 
 diseases such as glaucoma, ALS, and FTD. Although many hypo-
theses explaining the consequences of these mutations have been 
suggested, clear mechanisms of pathogenesis caused by OPTN 
mutations are still not clear.
Several OPTN mutations have been identified in patients with 
ALS and FTD (4, 28–31). Also mutations in TBK1 have been 
linked with these diseases (5, 32, 33), suggesting a common 
pathway defect in these pathologies. The ALS-associated TBK1 
E696K mutation specifically abolishes its binding to OPTN and 
disrupts OPTN/TBK1 complex formation (23, 34), this in con-
trast to the glaucoma-associated OPTN E50K mutation, shown 
to cause death of retinal ganglion cells in vitro and in transgenic 
mice (35), which enhances the interaction between OPTN and 
TBK1, affecting the oligomeric state of OPTN (34). However, 
many ALS-associated OPTN mutations map to the C-terminal 
part of the protein, and not to the N-terminal TBK1-binding 
region, making it unlikely that these mutations will affect the 
interaction between OPTN and TBK1. These mutations may, 
however, disturb the ubiquitin-binding function of OPTN and 
may hint to a defect in the process of selective autophagy (34) or 
to a defect in OPTN’s ability to suppress NF-κB activation and 
apoptosis via linear ubiquitin binding (11). A recent study sug-
gests that OPTN protects from neurodegeneration and ALS by 
suppressing RIPK1-dependent signaling and necroptosis, a form 
of regulated necrotic cell death (Figure 2F) (36). Indeed, OPTN-
deficient mice develop progressive demyelination and axonal 
degeneration, reminiscent of ALS, due to CNS cell necroptosis 
and neuroinflammation, a phenotype which could be rescued 
by inhibiting RIPK1 kinase activity preventing necroptosis in 
OPTN-deficient mice (36). OPTN has also been shown to protect 
motor neurons from TNF-induced apoptosis, through associa-
tion with caspase 8 at its dead effector domains to prevent the 
recruitment of FADD and downstream caspase activation (11). 
In agreement, cleaved caspase 3 was detected in motor neurons 
from OPTN-associated ALS patients, suggesting enhanced apop-
tosis in the absence of OPTN (11). Besides these signs of motor 
neuron apoptosis, intracytoplasmic inclusions in brain samples 
from patients with OPTN mutations often stain positive for linear 
ubiquitin and activated NF-κB (11).
Genetic variants of OPTN leading to lower OPTN expression 
have also been identified in patients with Paget’s bone disease 
(3, 37). OPTN was shown to act as a negative regulator of osteo-
clast differentiation, and mice with a loss-of-function mutation 
in the UBD of OPTN have increased osteoclast activity and bone 
turnover (38).
Finally, OPTN has been associated with Crohn’s disease (CD), 
and diminished expression of OPTN was observed in approxi-
mately 10% of CD patients (39, 40). Patient-derived macrophages 
show decreased pro-inflammatory cytokine secretion, suggesting 
an effect on inflammatory responses and bacterial clearance, 
as is observed in CD (39, 40). In agreement, loss of OPTN in 
mice was shown to impair cytokine production and neutrophil 
recruitment in a bacteria-dependent model of colitis (40, 41). 
However,  contrary to the bacteria-driven colitis, OPTN knockout 
mice respond normally to the model of dextran sodium sulfate-
induced colitis (17, 41). This difference in response between both 
colitis models might suggest a specific role for OPTN in protection 
from bacterial infection and infection-associated IBD. Recently, 
OPTN has been implicated in CD through its interaction with 
the endoplasmic reticulum (ER) stress sensor IRE1α, via which it 
was suggested to participate in the removal of ER membranes in 
conditions of prolonged ER stress (42). Defective autophagy and 
ER stress in intestinal epithelial cells induce IRE1α aggregation, 
triggering intestinal inflammation. However, these IRE1α aggre-
gates can be recruited to autophagosomes via OPTN, followed 
by IRE1α degradation (42). Hence, OPTN-dependent selective 
autophagy (ERphagy) may act as a mechanism to protect from 
prolonged ER stress and intestinal inflammation. Alternatively, 
since OPTN has previously been shown to localize to protein 
aggregates (43), OPTN could recognize the misfolded proteins 
and mediate their clearance independently of IRE1α.
COnCLUDinG ReMARKS
Optineurin has been implicated in many signaling pathways and 
cellular processes. Overall, three major protective mechanisms 
can be considered: regulation of selective autophagy, regula-
tion of inflammatory signaling, and protection from cell death. 
Mutations in OPTN, interfering with these protective activities, 
may eventually lead to disease. However, despite our knowledge 
on the role of OPTN in these cellular processes, we still know very 
little concerning the molecular mechanisms behind the disease-
associated OPTN mutations. Most of these mutations have only 
been studied upon overexpression in cell culture models and 
have never been validated in vivo. Since OPTN knockout mice 
nor OPTN mutant mice defective in ubiquitin binding (15–17) 
develop spontaneous disease, OPTN mutations most probably 
induce a gain-of-function, rather than a mere loss of its normal 
function. Hence, the development of OPTN knock-in models 
expressing specific disease-associated mutations will be crucially 
important to clarify the importance of these mutations for disease 
development and will help to better understand the biological 
functions of OPTN.
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